| Sep 30 2024 |
Cross-Border Catch-Up: China’s Retirement System [Podcast], |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Sep 27 2024 |
USTR Finalizes New Section 301 Tariffs |
Miller Canfield |
| Sep 26 2024 |
BIS Proposes Prohibitions on Connected Vehicles with Links to China and Russia: Nine Observations for Companies to Consider |
Blank Rome LLP |
| Sep 26 2024 |
For U.S. Manufacturers and Other Exporters, Recent Federal Strike Force Prosecutions Highlight Need To Evaluate Compliance Program Sufficiency |
Robinson & Cole LLP |
| Sep 26 2024 |
BIOSECURE Act: US to Target Chinese Biotechnology Companies |
McDermott Will & Emery |
| Sep 18 2024 |
White House and USTR Announce Changes to De Minimis Exception and Section 301 Tariffs |
Greenberg Traurig, LLP |
| Sep 17 2024 |
Artificial Intelligence and Intellectual Property Legal Frameworks in the Asia-Pacific Region |
Squire Patton Boggs (US) LLP |
| Sep 16 2024 |
BIS Issues Rule on Implementation of Export Controls on Several Advanced Technologies |
Squire Patton Boggs (US) LLP |
| Sep 16 2024 |
As the (Customs and Trade) World Turns: September 2024 |
ArentFox Schiff LLP |
| Sep 13 2024 |
China’s Implementation of Patent Term Adjustment |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 13 2024 |
United States | October Visa Bulletin |
Berry Appleman & Leiden |
| Sep 13 2024 |
The BR International Trade Report: September 2024 |
Blank Rome LLP |
| Sep 13 2024 |
October 2024 Visa Bulletin – New Fiscal Year, Mostly the Same Old Story |
Hunton Andrews Kurth |
| Sep 13 2024 |
China’s Supreme People’s Court Publishes Typical Cases on Anti-Monopoly and Anti-Unfair Competition |
Schwegman, Lundberg & Woessner, P.A. |
| Sep 11 2024 |
China | Fingerprint Collection Exemption Extended |
Berry Appleman & Leiden |
| Sep 10 2024 |
BIOSECURE Act: Anticipated Movement, Key Provisions, and Likely Impact |
Foley & Lardner LLP |
| Sep 10 2024 |
CNIPA Releases 4th FAQ on Patent Open Licensing – Handling of Relevant Legal Formalities |
Schwegman, Lundberg & Woessner, P.A. |
| Sep 9 2024 |
GT Newsletter | Competition Currents | September 2024 |
Greenberg Traurig, LLP |
| Sep 9 2024 |
China Expands Pilot Program for Foreign Investment in the Healthcare Sector |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 9 2024 |
Sichuan Patent Agents Stage Boycott |
Schwegman, Lundberg & Woessner, P.A. |
| Sep 7 2024 |
CNIPA Releases Third FAQ on Patent Open Licensing – Withdrawal of Patent Open Licensing Declaration |
Schwegman, Lundberg & Woessner, P.A. |
| Sep 6 2024 |
China Regulator Issues Administrative Measures and New Negative List for Cross-border Transfers in China (Beijing) Pilot Free Trade Zone |
Hunton Andrews Kurth |
| Sep 5 2024 |
CNIPA Releases FAQ 2 on Patent Open Licensing – Recordation of Patent Open Licensing Contracts |
Schwegman, Lundberg & Woessner, P.A. |
| Sep 5 2024 |
China Calls for Submissions of New Health Claims |
Keller and Heckman LLP |
| Sep 4 2024 |
Foley Automotive Update 04 September 2024 |
Foley & Lardner LLP |
| Sep 4 2024 |
CNIPA Releases FAQ On Patent Open Licensing – Submission of Patent Open Licensing Declaration |
Schwegman, Lundberg & Woessner, P.A. |
| Aug 28 2024 |
Asia-Pacific: 2024 Elections and Immigration News |
Berry Appleman & Leiden |
| Aug 27 2024 |
China Proposed New Anti-Monopoly Guidelines for the Pharmaceutical Sector |
Sheppard, Mullin, Richter & Hampton LLP |
| Aug 26 2024 |
China Releases Draft Guidelines for Front-of-Pack Nutrition Labeling |
Keller and Heckman LLP |
| Aug 20 2024 |
Highlights of the Draft Amendment to the Arbitration Law of China |
Sheppard, Mullin, Richter & Hampton LLP |
| Aug 19 2024 |
Three Key Takeaways from CFIUS's 2023 Annual Report |
Mintz |
| Aug 19 2024 |
CNIPA Releases Report on National Intellectual Property Agency Industry Development Status (2023) |
Schwegman, Lundberg & Woessner, P.A. |
| Aug 18 2024 |
CNIPA: Frequently Asked Questions re Fees for Open Licensing and Patent Term Compensation |
Schwegman, Lundberg & Woessner, P.A. |
| Aug 15 2024 |
Cross-Border Catch-Up: Leave Policies in China [Podcast] |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Aug 14 2024 |
China’s State Administration for Market Regulation Releases Draft Antitrust Guidelines for the Pharmaceutical Sector Covering Reverse Payments and Evergreening |
Schwegman, Lundberg & Woessner, P.A. |
